Tragara Pharmaceuticals Raises $40M

San Diego-based Tragara Pharmaceuticals announced this morning that it is developing therpaties for the treatment of cancer and inflammatory disease, and has closed $40M in a Series A funding. The new company said that it formally launched operations in January. Investors in the firm include Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners, and Mitsubishi International Corporation. Tragara's management team comes from Cabrellis Pharmaceuticals. More information »